Weighted Blankets With Infants With NAS

Status Completed

Clinical Trial Summary

Infants with neonatal abstinence syndrome (NAS) who are cared for in a Neonatal Intensive Care Unit (NICU) often display symptoms including hyperactivity, irritability, jitteriness, poor feeding, and poor sleep patterns. The recommended first line of treatment to relieve these symptoms involves nonpharmacological interventions. The purpose of the current pilot study is to provide preliminary data to assist in the design of a larger scale study to examine one nonpharmacological intervention, weighted blankets. The pilot study will assess the feasibility of a cross-over randomized controlled design to study the impact of a weighted blanket on infants' symptoms of NAS.

The aims of the study are:

Aim1: To determine the feasibility of recruiting patients for a study evaluating the use of weighted blankets in the care of infants with NAS Aim 2: To determine the feasibility and safety of the study procedures Aim 3: To examine whether there is clinical benefit to using weighted blankets for the treatment of symptoms in infants with NAS.

After informed consent is obtained, infants will be randomized to have either a weighted blanket or a non-weighted blanket placed on them first. A cross-over design will be used so all infants will experience both the non-weighted and weighted blankets. Thirty minutes before each feeding, baseline vital signs and Finnegan score will be obtained. Then, a blanket (weighted or non-weighted) will be placed on the infant for 30 minutes. Infants will be directly monitored and on heart rate/respiratory rate monitors while the blanket is applied. Vital signs and Finnegan scores will be obtained at the end of 30 minutes of blanket placement, infants will be fed, and vital signs and Finnegan scores will be obtained again 30 minutes after the blanket was removed. Descriptive statistics will be used to determine the enrollment rate and feasibility of the protocol. Nonparametric statistics will be used to compare total Finnegan scores for infants with the weighted blanket applied compared to infants with a non-weighted blanket applied. Changes in Finnegan scores will be examined to estimate an effect size to use in a power analysis for a future larger effectiveness study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03113656
Study type	Interventional
Source	TriHealth Inc.
Contact
Status	Completed
Phase	N/A
Start date	July 14, 2017
Completion date	January 18, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01965704` - Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women	Phase 2
Completed	`NCT03890562` - Assessing the Effects of Auricular Acupressure on Newborns With NAS	N/A
Completed	`NCT01958476` - Improving Outcomes in Neonatal Abstinence Syndrome	Phase 3
Active, not recruiting	`NCT01734551` - NAS Treatment - Opiate Versus Non-Opiate	Phase 4
Completed	`NCT00496951` - Vagal Tone and Neonatal Abstinence Syndrome	N/A
Completed	`NCT02851303` - Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome	Phase 4
Recruiting	`NCT05226624` - The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program	N/A
Completed	`NCT03670160` - Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome	Phase 2
Not yet recruiting	`NCT04611659` - Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine	N/A
Completed	`NCT01452789` - Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome	Phase 3
Completed	`NCT04588519` - tAN to Mitigate Withdrawal Behaviors in Neonates	N/A
Completed	`NCT02797990` - Conflict Between Maternal Autonomy and Child Health in Substance-use	N/A
Completed	`NCT02801331` - Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome	N/A
Terminated	`NCT03246243` - Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Completed	`NCT03567603` - Sound Processing Changes in Babies With Opioid Exposure
Recruiting	`NCT06303986` - Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
Active, not recruiting	`NCT03725332` - The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky	N/A
Recruiting	`NCT04983563` - Actigraphy and Neonatal Abstinence Syndrome of Hospitalized Newborn in Intensive Care Units	N/A
Completed	`NCT04298853` - Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome	Phase 4
Completed	`NCT02182973` - Donor Human Milk in Neonatal Abstinence Syndrome

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.